When CRC cells are in the hypoxia microenvironment, tanshinone IIA inhibits angiogenesis by targeting TGF-β1 and inhibiting the HIF-1α/β-Catenin/VEGF pathway (163). Here, HIF1A is linked to colorectal carcinoma.